Clinical utility of vinblastine therapeutic drug monitoring for the treatment of infantile myofibroma patients: A case series.
Vickyanne CarruthersShelby BarnettRebecca ReesTasnim ArifOlga SlaterRamya RamanujacharKatie JohnsonSarah BrownCatherine GrahamG A Amos BurkeGareth J VealPublished in: Pediatric blood & cancer (2022)
Infantile myofibroma is a rare, benign tumour of infancy typically managed surgically. In a minority of cases, more aggressive disease is seen and chemotherapy with vinblastine and methotrexate may be used, although evidence for this is limited. Chemotherapy dosing in infants is challenging, and vinblastine disposition in infants is unknown. We describe the use of vinblastine therapeutic drug monitoring in four cases of infantile myofibroma. Marked inter- and intrapatient variability was observed, highlighting the poorly understood pharmacokinetics of vinblastine in children, the challenges inherent in treating neonates, and the role of adaptive dosing in optimising drug exposure in challenging situations.
Keyphrases
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- locally advanced
- young adults
- peritoneal dialysis
- prognostic factors
- high dose
- squamous cell carcinoma
- emergency department
- weight gain
- body mass index
- chemotherapy induced
- smoking cessation
- adverse drug
- drug induced
- electronic health record